Tests PF-07328948 pill in adults with heart failure
Tests a new study pill against a placebo in adults with heart failure.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Key facts
- Where
- Baltimore, Beverly Hills, Bowie, Brownsville, Chicago, Evanston, Fort Wayne, Fort Worth, Hazel Crest, Jacksonville, Lake Forest, Lima, Lincoln, McKinney, Miami, North Miami Beach, Pembroke Pines, Richmond, Santa Maria, Tomball, and Winter Park, United StatesSee the 30 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT06991257, who can take part
Where in United States
- Ascension Saint Agnes Heart CareBaltimore, United StatesTaking people
- National Heart InstituteBeverly Hills, United StatesNo longer taking part
- Chesapeake Cardiac CareBowie, United StatesTaking people
- Flourish Research - BowieBowie, United StatesTaking people
- Headlands Horizons, LLC dba Headlands Research-BrownsvilleBrownsville, United StatesTaking people
- Valley Regional Medical CenterBrownsville, United StatesTaking people
- NMH Clinical Research UnitChicago, United StatesTaking people
- Northwestern Memorial HealthCare - Arkes PavilionChicago, United StatesTaking people
- Northwestern Memorial HealthCare - Feinberg PavilionChicago, United StatesTaking people
- Northwestern Memorial HealthCare - Galter PavilionChicago, United StatesTaking people
- Northwestern Memorial Hospital Investigational Drug Service (IDS)Chicago, United StatesTaking people
- Northwestern UniversityEvanston, United StatesTaking people
- NexGen ResearchFort Wayne, United StatesTaking people
- Texas Health Physicians GroupFort Worth, United StatesTaking people
- Texas Health Research & Education Institute - Fort WorthFort Worth, United StatesTaking people
- Chicago Medical ResearchHazel Crest, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- Orange County Research CenterLake Forest, United StatesNo longer taking part
- NexGen ResearchLima, United StatesTaking people
- Velocity Clinical Research, Lincoln, Pioneer Heart InstituteLincoln, United StatesTaking people
- North Dallas Research AssociatesMcKinney, United StatesTaking people
- Flourish Research Acquisition, LLC dba Flourish Research - North MiamiMiami, United StatesTaking people
- Infinite Clinical ResearchMiami, United StatesTaking people
- Amavita Research ServicesNorth Miami Beach, United StatesTaking people
- DBC Research USA, CorpPembroke Pines, United StatesTaking people
- Reid Physician AssociatesRichmond, United StatesTaking people
- Comprehensive Cardiovascular CareSanta Maria, United StatesTaking people
- FOMAT Medical ResearchSanta Maria, United StatesTaking people
- Northwest Houston Heart CenterTomball, United StatesTaking people
- Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06991257EU 2024-518438-94-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).Read full original descriptionShow less
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Inclusion: aged 18 years to < 80 years; clinically confirmed to have a diagnosis of heart failure for at least 3 months; New York Heart Association Class II-IV symptoms; left ventricular ejection fraction greater than 40%; Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85; Six-minute walking distance greater than 75 meters.
Exclusion: Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor; Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor; Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body; History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes.
This study is seeking participants who are:.